Study of MRA in Patients With Rheumatoid Arthritis (RA)
- Sponsor
- Chugai Pharmaceutical
- Study ID
- NCT00144651
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- MRA(Tocilizumab) — DRUG8mg/kg/4 weeks for 1 year
Study Details
This is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.
Key Dates
- Start date
- Aug 31, 2001
- Status verified
- Aug 2013
- Primary completion
- Jun 30, 2009
- Completion
- Jun 30, 2009
Study Design
- Enrollment
- 135 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: 1
Primary Outcome Measure
ACR 20% responder rate compared to the pre-treatment in the preceding study [ Time Frame: throughout study ]
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Early Rheumatoid Arthritis Lung Disease StudyRecruiting · University of Nebraska · Omaha, Nebraska
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina